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Silje.Rafaelsen@uib.noAbstractObjective: Hereditary hypophosphatemias (HH) are rare monogenic conditions characterized by decreased renal tubular
phosphate reabsorption. The aim of this study was to explore the prevalence, genotypes, phenotypic spectrum, treatment
response, and complications of treatment in the Norwegian population of children with HH.
Design: Retrospective national cohort study.
Methods: Sanger sequencing and multiplex ligand-dependent probe amplification analysis of PHEX and Sanger sequencing
of FGF23, DMP1, ENPP1KL, and FAM20C were performed to assess genotype in patients with HH with or without rickets in all
pediatric hospital departments across Norway. Patients with hypercalcuria were screened for SLC34A3 mutations. In one
family, exome sequencing was performed. Information from the patients’ medical records was collected for the evaluation
of phenotype.
Results: Twety-eight patients with HH (18 females and ten males) from 19 different families were identified. X-linked
dominant hypophosphatemic rickets (XLHR) was confirmed in 21 children from 13 families. The total number of inhabitants
in Norway aged 18 or below by 1st January 2010 was 1 109 156, giving an XLHR prevalence of w1 in 60 000 Norwegian
children. FAM20C mutations were found in two brothers and SLC34A3 mutations in one patient. In XLHR, growth was
compromised in spite of treatment with oral phosphate and active vitamin D compounds, with males tending to be more
affected than females. Nephrocalcinosis tended to be slightly more common in patients starting treatment before 1 year of
age, and was associated with higher average treatment doses of phosphate. However, none of these differences reached
statistical significance.
Conclusions: We present the first national cohort of HH in children. The prevalence of XLHR seems to be lower in Norwegian
children than reported earlier.ice
.0 UEuropean Journal of
Endocrinology
(2016) 174, 125–136IntroductionHereditary hypophosphatemia (HH) is a group of rare
diseases with disordered phosphate metabolism and
decreased renal tubular phosphate reabsorption (1). In
hypophosphatemic rickets (HR), the hypophosphatemia
is associated with rickets and osteomalacia, whereas
syndromes with hypophosphatemia combined withosteosclerosis and ectopic calcifications, and not rickets
or osteomalacia, are also recognized (1).
HR can be classified as either dependent or indepen-
dent of the bone derived fibroblast growth factor 23
(FGF23) (1). FGF23 is a phosphate-regulating hormone (2),
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174 :2 126sodium-phosphate co-transporter types IIa and IIc (NaPi-
IIa and NaPi-IIc) encoded by SLC34A1 and SLC34A3
respectively. Elevated levels of serum phosphate increase
the expression of FGF23 thereby decreasing the reabsorp-
tion of phosphate in the renal proximal tubule, while
hypophosphatemia normally down regulates the
expression of FGF23. FGF23 also down regulates the1-a-
hydroxylase (encoded by CYP27b1), thus inhibiting the
activation of 25OH vitamin D (25OHD) to 1,25(OH)2
vitamin D (1,25(OH)2D), and up regulates 24-hydroxylase
(encoded by CYP24a1), which inactivates 1,25(OH)2D
by conversion to 24,25(OH)2 vitamin D (3). In FGF23-
dependent HR, the physiological increase in serum
1,25(OH)2D in response to hypophosphatemia is blunted,
and the result is a serum level of 1,25(OH)2D that is low,
or inappropriately normal for the degree of hypo-
phosphatemia (4).
FGF23 dependent HR is caused by mutations in genes
involved in the FGF23 bone–kidney-axis, with levels of
intact FGF23 (iFGF23) being elevated or inappropriately
normal in the setting of hypophosphatemia when
suppressed FGF23 is to be expected (1). FGF23 dependent
HR includes X-linked dominant HR (XLHR) caused by loss-
of-function mutations in the phosphate regulating endo-
peptidase homolog, X-linked (PHEX) gene (5), autosomal
dominant HR caused by gain of function mutations in the
FGF23 gene (6), and three types of autosomal recessive HR.
ARHR1 is caused by mutations in the DMP1 gene,
encoding the dentin matrix protein 1 (7, 8), ARHR2
is caused by mutations in the ENPP1 gene encoding
the ectonucleotide pyrophosphatase/phosphodiesterase 1
(9, 10), whereas we have recently shown an association
between biallelic mutations in FAM20C and FGF23-
dependent ARHR3 in a Norwegian family (11). FAM20C
encodes a protein kinase, important in many phosphoryl-
ation processes. Phosphorylation of FGF23 by FAM20C
makes FGF23 less stable by inhibiting O-glycosylation by
GalNacT3 (12), and inactivating mutations in FAM20C
thus leads to increased levels of iFGF23 (11, 13). There is
also one report of FGF23 dependent HR caused by an
activating translocation leading to up-regulation of the
expression of the KL gene, encoding the anti-aging protein
a-klotho (14). In FGF23-independent HR, as seen in
hereditary HR with hypercalcuria (HHRH) caused by
mutations in the SLC34A3 gene (15, 16), the level of
iFGF23 is appropriately down-regulated (16).
Treatment of HR includes oral phosphate replacement
several times daily, combined with calcitriol to counteract
the secondary hyperparathyroidism (HPT) elicited by
the serum phosphate peak (17) and transient decreasewww.eje-online.orgin serum ionized calcium upon phosphate dosing.
Treatment is balanced to improve linear growth and
reduce skeletal deformities while simultaneously mini-
mizing the risk of complications to treatment such as
secondary and tertiary HPT, nephrocalcinosis, hyper-
tension, and renal failure (18).
We have conducted the first complete national study
of HH in children, to explore the prevalence, genotypes,
phenotypic spectrum, and response to and complications
of treatment.Subjects and methods
Patient population
During 2009 all pediatric hospital departments in Norway
were contacted to identify children with HH. The number
of patients identified was compared to the number of
patients younger than 18 years registered in the Norwe-
gian Patient Registry (NPR) with the diagnosis code ‘E83.3
Disorders of phosphorus metabolism and phosphatases’
in the World Health Organization’s International Classi-
fication of Diseases version 10 (WHO ICD-10). Patients
were continuously recruited through the years 2009–2014.
The inclusion criteria for HH were serum phosphate
below the age dependent reference range in repeated
samples combined with tubular maximum reabsorption
rate of phosphate per glomerular filtration rate (TmP/GFR)
not due to primary HPT, HPT secondary to renal failure or
malabsorption, Fanconi syndrome or other tubulopathy,
vitamin D dependent rickets, vitamin D deficiency or
hypophosphatemia secondary to acute metabolic
derangements. A family history or genetic diagnosis was
supportive, but not required for inclusion.Genetic analysis
Genomic DNA was purified from blood using the
QiaSymphony System (Qiagen). If the mutation status
was not already known, all exons and intron–exon
boundaries of PHEX were sequenced in the index case of
each family. If a disease causing mutation was not found,
and the inheritance pattern suggested a sporadic case or
X-linked dominant disease, multiplex ligand-dependent
probe amplification (MLPA) analysis of PHEX were
performed at the Molecular Genetics Laboratory, Royal
Devon and Exeter Foundation NHS Trust, Exeter, Devon,
UK. The PHEX MLPA analysis can identify mid-size
deletions and insertions not detected by regular Sanger
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174 :2 127All exons and intron–exon boundaries of FGF23,
DMP1, ENPP1, KL, and FAM20C were sequenced, in
successive order, in subjects without pathogenic PHEX
mutations.
In short, DNA targets were first amplified by PCR (list of
primers available upon request) using the AmpliTaq Gold
DNA Polymerase System (Applied Biosystems). PCR ampli-
cons were purified with 2 ml of ExoSapIT. Using the Big Dye
Terminator chemistry sequencing was performed on the
3730 DNA analyzer (Applied Biosystems) and analyzed
using the SeqScape Software (Applied Biosystems).
All mutations detected were compared to variants
previously reported in the SNP database (http://www.ncbi.
nlm.nih.gov/projects/SNP/index.html) and in the PHEX
database (http://www.pahdb.mcgill.ca/cgi-bin/phexdb/
phexdb_mutQ1.cgi?fieldZID_mut&valueZ).Review of medical history
Information on age at diagnosis, clinical and biochemical
findings at diagnosis, treatment, and complications was
collected by review of the medical records of included
patients. Height was converted to z-scores according to
Norwegian growth charts (19). Delta z-score was calcu-
lated as the difference between z-score at last registered
consultation and z-score at diagnosis. Laboratory data
from each visit from the time of diagnosis to the time of
inclusion in the study, including serum levels of calcium,
phosphate, alkaline phosphatase, creatinine, parathyroid
hormone (PTH), 25OHD, and 1,25(OH)2D were also
recorded, as well as results from kidney ultrasound and
skeletal X-ray examinations. TmP/GFR was calculated
according to the formula provided by Barth et al. (20).
Blood tests were analyzed according to each hospital
laboratory’s current standard methods.Genotype–phenotype associations in XLHR patients
The PHEX mutations were classified as either deleterious
or plausible according to earlier studies (21). Deleterious
mutations comprise those leading to a premature stop
codon, including nonsense mutations, splice-site
mutations, and insertions and deletions affecting reading
frame. Mutations classified as plausible were missense
mutations and deletions that did not affect reading frame.
The phenotypic features compared were age at diagnosis
and at the last registered consultation, height z-score at
diagnosis and at the last registered consultation, serum
levels of phosphate, ALP and PTH at diagnosis, skeletal
manifestations (clinical or radiological signs of rickets orbowing) at diagnosis, and information on dental involve-
ment, nephrocalcinosis, and persistent bowing at the last
registered consultation.Statistical analysis
The prevalences of HH and XLHR was calculated based on
the number of patients aged 0–18 years registered with
these diagnosis in 2009 and the total number of people in
Norway aged 0–18 years by 1st January 2010, obtained
from the official Statistics Norway database (22).
The data were analyzed with SPSS version 22.
Between-group comparisons were performed using non-
parametric tests; medians were compared using the Mann–
Whitney U test, and frequencies were compared with the
Fisher’s exact test.Ethics and approvals
Written informed consent was obtained from all study
participants. The study was approved by the Regional
Committee for Medical and Health Research Ethics, Region
West, Norway (REK number 2009/1140).
Clinical Trial Registration (ClinicalTrials.gov) number:
NCT01057186.Results
HH patient cohort
By 31st December 2009 we had identified a total of 23
children aged 0–18 years with HH in Norway, and all
except one were included in this study. Two additional
patients with HH, one with confirmed XLHR, were born
before 2009, but diagnosed after 2010. By the end of 2009
the National Patient Registry reported 32 children with
the ICD-10 diagnosis ‘E83.3 Disorders of phosphate
metabolism and phosphatases’, but four of these patients
had hypophosphatasia, and five had transient hypopho-
sphatemia in the course of malignancy, premature birth,
or other underlying condition. On 1st January 2010, the
number of inhabitants aged below 18 years was 1 109 156,
and this gives a prevalence of HH of w1 in 45 000
children. XLHR was confirmed in 18 children, giving a
prevalence of w1 in 60 000. During the period from 1st
January 2010 to 31st December 2014, we included another
four patients, two of which immigrated to Norway in 2014
and two patients born to XLHR mothers after 2010.
The total of 28 patients included comprised
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174 :2 128(Supplementary Figure 1, see section on supplementary
data given at the end of this article). XLHR was confirmed
in 21 children. Twenty-two patients had a family history
of HR, while six were sporadic cases.Genotypes in HH
We identified the likely pathogenic mutation in 15 of the
19 HH pedigrees (79%). PHEX mutations were found in
21 subjects from 13 different pedigrees (Supplementary
Table 1, see section on supplementary data given at the
end of this article), and three of the XLHR probands were
sporadic. Of the 13 different PHEX mutations detected,
nine had not been previously reported in the SNP or PHEX
databases (see section ‘Materials and methods’). The nine
novel mutations comprised one large duplication, two
single nucleotide deletions leading to frameshift and
premature stop codons, two triplet deletions leading to
loss of one or more codons, two missense mutations, one
nonsense mutation, and one splice site mutation. One
male patient with HHRH was found to be compound
heterozygous for a splicing mutation, c.757-1GOA, and an
intronic deletion mutation, c.925C20_926-48del, in the
SLC34A3 gene. The c.757-1GOA affects the conserved
splice donor site of intron 7, and is predicted to cause
aberrant splicing. The c.925C20_926-48del mutation has
been reported previously (15). Two patients with com-
bined heterozygous mutations in FAM20C are described
elsewhere (11). In four patients, two sporadic cases inTable 1 Characteristics of the cohort of patients with hereditary h
All pat
Time of diagnosis
Sex (male/female) (n/n) 1
Family history of HH (n/N) 2
Age at diagnosis (years) 2.1 (0
Height (z-score) K0.9 (K
Skeletal diseaseb (n/N) 1
Treatment
Age at treatment start (years) 2.1 (0
Elemental phosphorus (mg/kg per day) 39 (
Alfacalcidol (ng/kg per day) 33 (
Last registered consultation
Age (years) 12.1 (1
Height (z-score) K1.4 (K
Delta z-score height (z-score) K0.1 (K
Dental involvement (n/N) 1
Nephrocalcinosis (n/N) 1
Persistent bowing (n/N) 1
n/N, number of patients with this characteristic/total number of patients.
aContinual variables are given as median (range).
bSkeletal disease: clinical or radiological signs of rickets, or skeletal axis deviati
cInformation missing for one patient.
www.eje-online.orgfemales and two males with affected mothers, we were not
able to identify a pathogenic mutation by standard Sanger
sequencing of PHEX, FGF23, DMP1, ENPP1 or KL, or by
PHEX MLPA.Phenotypes in HH
The median age at diagnosis was 2.1 years (range 0.1–15.5
years), and 26 of the 28 subjects were diagnosed before the
age of 7 years (Table 1 and detailed information for each
subject is given in Supplementary Table 2, see section on
supplementary data given at the end of this article).
Median age at the last registered consultation was
12.1 years (range 1.3–18.3).
Phenotype in XLHR " The 21 XLHR children comprised
16 females and five males. Their median age was 0.9 years
(range 0.1–15.5) at diagnosis, and 10.8 years (range 1.3–
18.0) at the last registered consultation. Growth was
compromised, and Fig. 1 illustrates the height z-scores
for 19 of the 21 XLHR patients related to age at diagnosis
and at the last registered consultation. Males tended to
have a lower height z-score than females (Table 2), both at
diagnosis and at the last registered consultation, whereas
delta z-score did not differ between the sexes. In
accordance with an earlier study (23), we analyzed the
XLHR patients’ data depending on initiation of treatment
before or after 1 year of age. There was no significant
improvement in height z-score in either treatment group.ypophosphatemiaa.
ients (nZ28) XLHR (nZ21)
0/18 5/16
2/28 18/21
.1 to 15.5) 0.9 (0.1 to 15.5)
6.5 to 1.0) K1.2 (K6.5 to 1.0)
7/28 13/21
.2 to 15.6) 1 (0.2 to 6.7)
28 to 61) 39 (0 to 74)
21 to 42) 34 (0 to 54)
.3 to 18.3) 10.8 (1.3 to 18.0)
6.31 to 0.8) K1.4 (K6.3 to 0.8)
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Figure 1
Growth in X-linked hypophosphatemic rickets. Ages at diag-
nosis and last registered consultation, and the corresponding
height z-scores for 19 of the 21 XLHR patients. The two outliers
represent two immigrant siblings who had not received any
medical care and did not start treatment until age 6 and
15 years respectively. The broken line represents the male
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174 :2 129One patient was treated with growth hormone (GH)
from the age of 11 years 10 months. His height z-score
improved from K2.9 at the last consultation before
initiation of GH to a final height of K1.9 S.D. at age
17 years (data not shown).
Clinical or radiological evidence of skeletal involve-




Age (years) 0.9 (0.5 to 15.5)
Height (z-score) K3 (K5.1 to 0.5) K
Skeletal diseaseb (n/N) 4/5
Treatment data
Age at treatment start (years) 1 (0.5 to 3.6)
Elemental phosphorus (mg/kg per day) 50 (32 to 64)
Alfacalcidol (ng/kg per day) 49 (37 to 54)
Last registered consultation
Age (years) 14.8 (6.5 to 16.3)
Height (z-score) K2.2 (K5.1 to K1.0) K
Delta z-score (z-score) 0 (K2.1 to 1.3) K
Dental involvement (n/N) 4/5
Nephrocalcinosis (n/N) 2/5
Persistent bowing (n/N) 4/5
n/N, number of patients with this symptom/total number of patients.
aContinual variables are given as median (range).
bSkeletal disease: clinical or radiological signs of rickets, or skeletal axis deviatiand nine out of 15 females) at diagnosis. The seven
patients without skeletal manifestations at diagnosis were
all familial cases, diagnosed before the age of 8 months
(median 4 months), and comprised six females and one
male. During the years after diagnosis, all of these had
episodes of rickets identified on clinical or radiological
examination, and a male and two of the females had
persisting skeletal axis deviations at the last registered
consultation. Overall, nine females and four males had
persisting axis deviation at the last registered consultation,
and correcting osteotomy had been performed in one
female and two males. The prevalence of dental involve-
ment was higher in male than female XLHR patients,
and in children who started treatment after the age of
1 year (Table 2).
Genotype–phenotype associations in XLHR " There
were no differences between the mutation status groups
in growth, dental involvement, persistent bowing, or
development of nephrocalcinosis (results not shown).
Treatment and complications in HH
The median age at the start of treatment was 2.1 years.
Twenty-six of the 28 patients were treated with oral
phosphate and vitamin D (alfacalcidol) supplements
(Table 1). Two patients were diagnosed at the time of
inclusion, and had not started any treatment at that point.
Treatment and complications in XLHR " Details of
medical treatment were available for 19 of the 21 XLHRhypophosphatemic ricketsa.
gender Age at treatment start
Female (nZ16) !1 year (nZ10) O1 year (nZ9)
1.5 (0.1 to 6.5) 0.4 (0.1 to 0.9) 3.3 (0.7 to 15.5)
0.9 (K6.5 to 1.0) K0.8 (K3.0 to 1.0) K2 (K6.5 to 0.5)
9/15 3/10 9/9
1.1 (0.2 to 6.7) 0.6 (0.2 to 1.0) 3.6 (1.2 to 15.6)
32 (0 to 74) 59 (11 to 74) 35 (28 to 67)
28 (0 to 48) 42 (17 to 54) 26 (17 to 37)
7.9 (1.3 to 18.0) 11.1 (1.3 to 18.0) 8.4 (3.2 to 16.3)
1.4 (K6.3 to 0.8) K1.4 (K2.6 to 0.8) K2 (K6.3 to 0.3)
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174 :2 130patients. In this group, the median age at the start of
treatment with oral phosphate and alfacalcidol was 1.0
year (range 0.2–15.6), and ten of 19 children started
treatment before the age of 1 year.
Information concerning development of nephrocalci-
nosis was available for 20 of 21 XLHR patients, and
nephrocalcinosis was diagnosed in nine of 20 (45%),
at a median age 4 years 6 months (range 1 year–5 years
5 months), after a median time in treatment of 1 year
5 months (range 8 months–4 years 5 months). The
median time in treatment for patients without registered
nephrocalcinosis was 7 years 2 months (range 0–14 years
7 months).
All nine XLHR patients who developed nephrocalci-
nosis did so within 5 years of treatment. Of the 11 patients
without nephrocalcinosis, only four had been treated for
5 years or more, and were included in further compari-
sons. The prevalence of nephrocalcinosis in this subgroup
was nine of 13 (69%). There was a trend toward a higher
average daily dose of phosphate (given as mg/kg per day
elemental phosphorus) during the years before the
diagnosis of nephrocalcinosis as compared to the daily
phosphate dose during the first 5 treatment years in
patients without nephrocalcinosis (Fig. 2A) (median
61.0 mg/kg per day (range 12.1–79.0) and median
44.8 mg/kg per day (range 13.8–64.7) respectively). More-
over, there was a tendency for earlier start of treatment in
children who developed nephrocalcinosis compared
with children that did not (median 0.5 year vs 1 year;
range 0.2–4.4 vs 0.6–3.6), and seven of nine children with
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Figure 2
Complications in X-linked hypophosphatemic rickets.
(A) Nephrocalcinosis: the average daily phosphate (given as
mg/kg per day elemental phosphorus) dose in patients who
developed nephrocalcinosis (NCC) and patients who did not
(NCK). The horizontal lines represent the median in each group.
(B) Hyperparathyroidism: the relationship between the maxi-
mum registered value of serum PTH and phosphate dose (given
as mg/kg per day elemental phosphorus) at the same time point.
www.eje-online.orgnephrocalcinosis had started treatment before 1 year of
age. There were no differences in the starting doses of
phosphate and alfacalcidol, average daily dose of alfacal-
cidol, serum level of PTH level at diagnosis, maximum
registered serum PTH, or maximum registered urine-
calcium/creatinine ratio (U-Ca/creatinine; results not
shown). Furthermore, the groups did not differ with
respect to the occurrence of skeletal symptoms at
diagnosis, dental involvement at diagnosis, persistent
bowing at the last registered consultation, or delta height
z-score (not shown).
Information concerning parathyroid state was avail-
able in 18 patients, of whom 16 had elevated levels of total
intact PTH at the time of diagnosis (Table 1 and
Supplementary Table 2a). All patients developed transient
HPT during treatment in the face of normocalcemia. As
seen in Fig. 2B, there was a positive association between
the maximum measured serum PTH and the daily dose
of phosphate (given as mg/kg per day of elemental
phosphorus). Tertiary HPT was diagnosed in one female
XLHR patient at 13 years of age. She had been treated with
phosphate and alfacalcidol from the age of 5 months, and
during the 12.5 years of treatment, the average phosphate
dose was 83.0 mg/kg per day (range 47.0–127.0 mg/kg
per day) and alfacalcidol dose 18.5 ng/kg per day (range
11.4–44.0 ng/kg per day). Treatment with calcimimetics
was started, and she has avoided the need of para-
thyroidectomy (24).
Treatment and complications in non-X-linked
HH " Nephrocalcinosis was diagnosed in one female
patient with no detected mutation in any of the known
genes at age 8 years 2 months after 6 years 4 months of
treatment with phosphate and alfacalcidol. Nephrocalci-
nosis was also demonstrated in the male patient with
HHRH, before start of treatment. Tertiary HPT was found
in one female patient with no established mutations in
any of the known genes. She had been treated for 14 years,
with an average dose of elemental phosphorus of
45.9 mg/kg per day (range 38–80 mg/kg per day) and
alfacalcidol 34.2 ng/kg per day (range 22–49.6 ng/kg per
day) the last 7 years before the development of perma-
nently elevated PTH combined with hypercalcemia. The
patient has responded well to treatment with a calcimi-
metic, and has so far not needed parathyroidectomy.Discussion
We have presented the first national cohort of HH and
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174 :2 131phenotypic spectrum, and response to and complications
of treatment in the Norwegian pediatric population. The
prevalence of XLHR in Norwegian children was one in
60 000. Earlier reports from regional cohorts, with a risk of
selection bias, have found the prevalence of XLHR to be
w1 in 20 000 (25, 26). Studies of large pedigrees of XLHR
patients have reported a low penetrance of skeletal
manifestations in hypophosphatemic female family
members, whereas all hypophosphatemic males had
skeletal manifestations of disease (27). Hence, there is a
possibility of undiagnosed XLHR in Norwegian females
from pedigrees without affected males. However, the ratio
of female to male patients in our cohort was 16:5, as
compared to the expected ratio of 2:1 for X-linked
dominant disorders; a large proportion of undiagnosed
females thus seems unlikely. Since our study included only
children already in contact with health care and asympto-
matic members of the pedigrees were not tested for
hypophosphatemia, we cannot rule out hypophosphate-
mic second-degree relatives (28). It is therefore possible
that the prevalence of HH and XLHR in the Norwegian
pediatric population may be higher than one in 45 000
and one in 60 000 respectively.
We identified the genotype responsible for HH in 79%
of pedigrees in this population-based cohort, and PHEX
mutations comprised 87% of the verified mutations. This
supports what has been found by others (29), and confirms
that XLHR is the most common variant of HR. Of 13 PHEX
mutations, nine (69%) had not been reported earlier
(ExAC Browser accessed 21.05.15, http://exac.broadinsti-
tute.org/gene/ENSG00000102174), demonstrating that
most mutations are private in this gene (28). We have
previously reported two male siblings with the first
identified association between compound heterozygous
mutations in FAM20C and FGF23 dependent hypo-
phosphatemia in humans (11). None of the patients had
mutations in FGF23, DMP1, ENPP1, or KL, confirming that
mutations in these genes rarely seem to be the cause of
HH. In four patients we did not find the likely disease
causing mutation. However, as illustrated by our finding
of FAM20C mutations (11), there are possibilities of
mutations in other genes associated with pathways
involving FGF23, phosphate reabsorption, and tissue
mineralization.
One adolescent male was compound heterozygous for
mutations in the SLC34A3 gene. He had no manifestations
of rickets, normal growth and bone mineral density, and
came to medical attention because of recurrent kidney
stones, accompanied by hypercalcuria, hypophosphate-
mia, suppressed PTH, and high 1,25(OH)2D. He had anovel splicing mutation c.757-1GOA affecting the con-
served splice donor site of intron 7, predicted to cause
aberrant splicing, and a previously reported intronic
deletion mutation, c.925C20_926-48del (15). Earlier
studies have shown that about 10% of homozygous and
16% of compound heterozygous carriers of mutations in
SLC34A3 presented with renal calcifications, without
evidence of skeletal involvement (30, 31). Thus, our case
is consistent with a phenotypic and genotypic hetero-
genesity in SLC34A3 related conditions, including HHRH.
When comparing non-sense PHEX mutations with
missense PHEX mutations likely to reduce protein
function, we did not find differences in growth, severity
of skeletal or dental disease, or in the prevalence of
treatment complications based on the type of mutation.
Our findings confirm the results of another recent study
(21), whereas other studies have suggested an association
between truncating mutations and a more severe skeletal
phenotype (32, 33, 34). However, even in subjects with the
same genotype, the skeletal phenotype seems to be very
variable and individual (35, 36). This might reflect
influence from other genetic variants in mineralization
and phosphate metabolism. Interestingly, it was recently
reported that patients homozygous or heterozygous
for the FGF23 sequence variant c.C716T (p.T239M,
rs7955866) had significantly lower levels of serum
phosphate and lower renal TmP/GFR than patients
homozygous for the WT allele (37). Another research
group have reported a weak, but significant association
between the c.C716T variant of FGF23 and lower
TmP/GFR and lower plasma intact PTH in healthy children
and adults (38). In none of the studies, it was possible to
show significantly higher levels of serum iFGF23 in
subjects carrying the c.C716T variant.
Evaluation of phenotype in XLHR showed that growth
was compromised, and there was a tendency for lower
height z-scores in males than females. Also, we found a
trend for males having a higher proportion of skeletal and
dental manifestations than females. As discussed above,
some studies points to a milder phenotype in females,
with slight hypophosphatemia and mild or no overt
skeletal disease (39, 40). There are also reports of slightly
lower serum levels of phosphate (40, 41) and more severe
skeletal disease in male than female XLHR patients (42).
Other studies have reported no gender differences in
skeletal phenotype (35, 43), but more severe dental
phenotype in post pubertal males than females (35, 44).
Thus, our findings support the notion of a more severe
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174 :2 132Dental involvement seemed to be less common in the
patients who started treatment before 1 year of age,
suggesting the importance of proper mineralization of
dentin prior to the eruption of teeth (45). On the other
hand, starting treatment before age 1 year did not lead to
an improved height z-score at the last registered consul-
tation. Some earlier studies have concluded that early start
of treatment had a positive effect on linear growth (23, 46).
In one study however, the height z-score was generally
higher in those who started treatment before the age of
1 year compared with those who started later, but declined
over time for those who started treatment early and
improved in those who started treatment later (46). We
found that treatment with phosphate and vitamin D
improved mineral homeostasis and rickets, but did not
fully correct skeletal axis deviation and to a lesser extent
correct the growth deficiency in HR. This adds support to
the theory that FGF23 may play a role in the normal
physiology of mineralized tissues independently phos-
phate regulation (18). Treatment with phosphate will lead
to transient increases in serum phosphate, which trigger
production and release of FGF23 (47) and PTH (48), further
aggravating the skeletal phenotype. Novel therapy with
FGF23 neutralizing antibodies has shown that inhibition
of excess FGF23 activity correct growth deficiency in mice
(49), and anti-FGF23 antibodies are currently being tested
in human XLHR (50, 51). It is possible that longitudinal
growth in HH patients reflects the individual severity of
and response to a disturbed FGF23 homeostasis, rather
than the severity of hypophosphatemia itself.
The patients who developed nephrocalcinosis had
started treatment earlier and had received higher daily
doses of phosphate, but did not have better growth
outcomes, than patients without nephrocalcinosis. Renal
function remained normal in all patients, except for
transient low-grade renal failure seen in the XLHR patient
with tertiary HPT. Our results strengthen the association
between higher phosphate doses and development of
nephrocalcinosis found in earlier studies (52, 53, 54, 55).
Early start of treatment as a risk factor for nephrocalcinosis
has been found by some (52), but not by others (23, 46, 56).
The prevalence of nephrocalcinosis in patients receiving
combination therapy with phosphate and calcitriol is
reported to be from 33 to 80% (median 59%) (23, 46, 52,
53, 54, 55, 56, 57, 58), but long term follow-up of mild
nephrocalcinosis in XLHR does not seem to affect renal
function (56). As discussed above, treatment with
phosphate and calcitriol has a certain positive effect on
growth, but only phosphate-treated patients develop
nephrocalcinosis (54, 55, 56). This again probablywww.eje-online.orgreflects that current treatment options are suboptimal,
both when considering skeletal outcome and the rate of
complications.
Elevated serum levels of PTH were found in ten of 15
XLHR patients before the start of treatment all patients
developed HPT during the course of treatment. Our
findings add to other reports of high normal or slightly
elevated levels of PTH in hypophosphatemic untreated
XLHR patients (59, 60, 61). In normal subjects, hypopho-
sphatemia will, through an increase in 1,25(OH)2D, reduce
PTH levels (62). Evidence also suggests an inhibitory
effect of FGF23 on PTH production (63). The explanation
for the inappropriate PTH response in untreated HR, and
the details of the interactions between phosphate, FGF23,
and PTH, still need further clarification.
Secondary HPT caused by oral phosphate supplements
can be counteracted by increasing the doses of calcitriol,
with the risk of developing hypercalcuria and nephrocal-
cinosis, or by reducing the phosphate dose, with the risk
of worsening rickets (64). However difficult, successful
management of HPT in XLHR is important, as HPT has
been associated with development of hypertension and
renal failure (24, 65), cardiac failure (66), and also brown
tumor in the mandible (67).
Two patients, one with XLHR, developed tertiary HPT
after long-term use of phosphate supplements. The XLHR
patient had received relatively high doses of phosphate
and relatively low doses of alfacalcidol for more than
10 years. Tertiary HPT has been reported in 36 cases of HR
(24, 65, 66, 68, 69, 70, 71, 72, 73, 74, 75), and prolonged
treatment with high doses of phosphate supplements
seems to be a risk factor (68, 71). There are reports of
successful treatment of tertiary HPT with cinacalcet in
children (24, 76) and adults (77, 78), but safety concerns
have stopped further clinical trials investigating the effects
of cinacalcet in children (79). A recent report suggests the
vitamin D analog paricalcitol to suppress elevated PTH
secondary to treatment in XLHR (80). However, careful
monitoring of treatment, to ensure lowest efficient
phosphate dose is very important to heal rickets and at
the same time reduce the risk of tertiary HPT.
The observations from this study support recently
published guidelines on treatment and monitoring of HR
in children (64, 81). We recommend that combined
treatment with oral phosphate and activated vitamin D
(calcitriol or alfacalcidol) is started once the diagnosis has
been made. Most children respond well to a calcitriol dose
of 20–30 ng/kg per day (divided in two doses) or
alfacalcidol 30–50 ng/kg per day (single dose) and an
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skeletal deformities. The starting doses of phosphate
should be kept low to reduce gastrointestinal side effects,
and to avoid complications clinical and biochemical
controls should be performed at least every 3 months,
and supplemented with skeletal X-rays every 2 years and
renal ultrasonography every 2–5 years. To avoid HPT, the
aim should not be normalization of serum phosphate, but
the lowest efficient dose that promote growth and heal
rickets. To minimize the risk of nephrocalcinosis, hyper-
calcuria, defined as U-Ca/creatinine ratio O0.87 mmol/
mmol should be avoided.
One strength of our study is related to the fact that
combined data from the NPR and all pediatric centers in
Norway allowed us to collect a complete national material
of childhood HH. This allowed for the estimation of a
national prevalence, and adds information to the litera-
ture on the epidemiology of hereditary HR. Moreover, we
have identified new mutations in known and novel genes,
expanding the genetic diversity of HH with and without
rickets. On the other hand, the study is limited by the size
of the cohort and the retrospective design, implying we
could not ensure uniform collection of information from
the clinical, biochemical, and radiological examinations.
Furthermore, we did not do genetic testing on normopho-
sphatemic, asymptomatic siblings, as predictive genetic
testing on children is not allowed in Norway according to
the Biotechnology Act. This means there is a possibility for
undiagnosed subclinical cases.
In conclusion, we have presented the first complete
national cohort of HH in children. The prevalence of
XLHR seems to be lower in Norwegian children than
reported earlier.
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